Antagonism of baclofen-induced antinociception by intrathecal administration of phaclofen or 2-hydroxy-saclofen, but not delta-aminovaleric acid in the rat.
This study evaluated the ability of two new, selective antagonists of the gamma-aminobutyric acidB (GABAB) receptor, phaclofen (PHAC) and 2-hydroxy-saclofen (2-OH-S), to antagonize the increase in tail-flick latency (TFL) and hot-plate latency (HPL) produced by i.t. administered baclofen (BAC) in the rat. The putative GABAB receptor antagonist delta-aminovaleric acid (DAVA) was also examined for comparative purposes. Intrathecal (i.t.) pretreatment with increasing doses of PHAC (10-100 micrograms) shifted the dose-effect relationship of i.t. administered BAC progressively to the right in a parallel manner in both the tail-flick (TF) and hot-plate (HP) test. Schild analysis of the data yielded an apparent pA2 value of 7.3 +/- 0.1 and a slope of -0.98 +/- 0.14. By comparison, PHAC did not antagonize the increase in HPL produced by i.t. injection of the serotonin1A agonist, 8-hydroxy-N,N-dipropyl-2-aminotetralin. These observations indicate that PHAC competitively and selectively antagonizes BAC and further suggest that the antinociceptive effects of i.t. administered BAC are mediated by the PHAC-sensitive subtype of the GABAB receptor. Intrathecal injection of PHAC alone did not decrease TFL or HPL, suggesting that spinal GABAB receptors involved in nociception are not tonically activated. Although i.t. pretreatment with 2-OH-S (10-30 micrograms) also antagonized the antinociceptive effects of i.t. administered BAC, increasing doses of 2-OH-S did not produce progressive, rightward shifts in the dose-effect relationship of BAC. Indeed, i.t. administration of 2-OH-S alone modestly increased TFL, but not HPL in the rat. These observations suggest that 2-OH-S may be a partial agonist at spinal GABAB receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Aran
S
S
Department of Anesthesia and Critical Care, University of Chicago, Illinois.
Hammond
D L
DL
D000596:Amino Acids / Q000008:administration & dosage / Q000494:pharmacology*; D021542:Amino Acids, Neutral; D000698:Analgesia; D000818:Animals; D001418:Baclofen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D007278:Injections, Spinal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000032:analysis / Q000187:drug effects
D000596:Amino Acids; D021542:Amino Acids, Neutral; D011963:Receptors, GABA-A; C052329:phaclofen; C013809:5-aminovaleric acid; D001418:Baclofen; C057491:2-hydroxysaclofen